home / stock / ruby / ruby news

RUBY News and Press, Rubius Therapeutics Inc. From 10/15/20

Stock Information
Company Name: Rubius Therapeutics Inc.
Stock Symbol: RUBY
Market: OTC
Website: rubiustx.com
Menu
RUBY RUBY Quote RUBY Short RUBY News RUBY Articles RUBY Message Board
Get RUBY Alerts

News, Short Squeeze, Breakout and More Instantly...
RUBY - Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer's Annual Meeting

CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the company will present precli...
RUBY - Seeking Alpha Catalyst Watch

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

RUBY - Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy Summit

CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that Laurence Turka, M.D., chi...

RUBY - Rubius Therapeutics Appoints Jose Carmona as Chief Financial Officer

CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Jose ȁ...
RUBY - Rubius Therapeutics (RUBY) Presents at H.C. Wainwright Annual Global Investment Conference - Slideshow

The following slide deck was published by Rubius Therapeutics, Inc. in conjunction with this Read more ...

RUBY - Rubius Therapeutics EPS beats by $0.03

Rubius Therapeutics (NASDAQ: RUBY ) : Q2 GAAP EPS of -$0.47 beats by $0.03 . More news on: Rubius Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

RUBY - Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across Pipeline

Strong Momentum in Dosing Patients and Manufacturing Clinical Supply for  RTX-240 Phase 1/2 Solid Tumor Clinical Trial Investigational New Drug Application on Track by Year-End for RTX-321 for HPV-Positive Cancers CAMBRIDGE, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Rubius Ther...
RUBY - Rubius Therapeutics to Announce Second Quarter 2020 Financial Results

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced plans to report second quarter ...

RUBY - Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing

CAMBRIDGE, Mass. , July 7, 2020 /PRNewswire/ -- Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes ther...

RUBY - Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma

Iveric Bio Goes Ahead with Second Pivotal Phase 3 Study of Zimura Iveric Bio ( ISEE ) announced that it has dosed the first patients for its second pivotal Phase 3 clinical trial GATHER2. The study seeks to evaluate Zimura’s potential for treating patients with geographic atrophy ...
Previous 10 Next 10